The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...

The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value ...

Since October 2020 – when the Health Sciences Authority (HSA) first authorized sale of an esketamine nasal spray ... to give numbers for Singapore, but Spravato is available at about 2,800 ...

Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray ... the ketamine nasal spray Spravato is now a mainstream prescription for ...

Yesterday, the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from a head-to-head study with a long-acting ...

SPRAVATO® (Esketamine): SPRAVATO® is an innovative treatment for treatment-resistant depression or depression with suicidal thoughts or actions. Administered under medical supervision ...

SPRAVATO® (Esketamine): SPRAVATO® is an innovative treatment for treatment-resistant depression or depression with suicidal thoughts or actions. Administered under medical supervision, this ...

Esketamine, the ketamine-derived nasal spray sold under the brand name Spravato (esketamine), is indicated for patients with treatment-resistant depression. In October 2023, the FDA warned about ...

Two cutting edge treatments for though-to-treat major depression are remarkably successful: TMS Therapy and Spravato (Esketamine) treatment. TMS is safe, medication free and covered by insurance.